Abstract
With the persistence of the SARS-CoV-2 pandemic and the emergence of novel variants, the development of novel vaccine formulations with enhanced immunogenicity profiles could help reduce disease burden in the future. Intranasally delivered vaccines offer a new modality to prevent SARS-CoV-2 infections through the induction of protective immune responses at the mucosal surface where viral entry occurs. Herein, we evaluated a novel protein subunit vaccine formulation containing a resistin-trimerized prefusion Spike antigen (SmT1v3) and a proteosome-based mucosal adjuvant (BDX301) formulated to enable intranasal immunization. In mice, the formulation induced robust antigen-specific IgG and IgA titers, in the blood and lungs, respectively. In addition, the formulations were highly efficacious in a hamster challenge model, reducing viral load and body weight loss. In both models, the serum antibodies had strong neutralizing activity, preventing the cellular binding of the viral Spike protein based on the ancestral reference strain, the Beta (B.1.351) and Delta (B.1.617.2) variants of concern. As such, this intranasal vaccine formulation warrants further development as a novel SARS-CoV-2 vaccine.
【초록키워드】 IgG, Vaccine, pandemic, spike, B.1.351, SARS-COV-2 infection, SARS-CoV-2 pandemic, body weight, variants of concern, Delta, B.1.617.2, viral entry, immunization, variants, SARS-CoV-2 vaccine, Spike protein, Antigen, Formulation, Protein, Neutralizing activity, Viral, Viral load, mice, persistence, immune responses, Lungs, Beta, Subunit vaccine, serum antibody, disease, SARS-CoV-2 infections, intranasal, Blood, protein subunit vaccine, binding, cellular, mucosal, reference strain, weight loss, viral spike protein, profile, protective immune response, help, serum antibodies, prefusion, offer, Body weight loss, IgA titers, Prevent, mucosal surface, resistin, robust, addition, evaluated, reducing, reduce, the SARS-CoV-2, 【제목키워드】 Vaccine, immunization, hamster, SARS-CoV-2 spike, immunogenic,